靶向癌症中的磷酸肌醇3-激酶通路。
Targeting the phosphoinositide 3-kinase pathway in cancer.
作者信息
Liu Pixu, Cheng Hailing, Roberts Thomas M, Zhao Jean J
机构信息
Department of Cancer Biology, Dana-Farber Cancer Institute, Pathology, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer. This pathway therefore presents both an opportunity and a challenge for cancer therapy. Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clinical trials, major issues remain. Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.
摘要
磷酸肌醇3激酶（PI3K）信号通路是一个关键的信号转导系统，它将癌基因和多种受体类型与许多重要的细胞功能联系起来，可能是人类癌症中最常被激活的信号通路。因此，该通路给癌症治疗带来了机遇和挑战。尽管针对PI3K亚型以及该通路中其他主要节点（包括AKT和雷帕霉素哺乳动物靶点（mTOR））的抑制剂已进入临床试验阶段，但主要问题依然存在。在此，我们重点介绍了在理解PI3K通路方面取得的最新进展，并讨论了开发针对该通路的癌症治疗药物的潜力和挑战。
相似文献
1
Targeting the phosphoinositide 3-kinase pathway in cancer.靶向癌症中的磷酸肌醇3-激酶通路。
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926.
2
PI3K and cancer: lessons, challenges and opportunities.PI3K 与癌症：教训、挑战与机遇。
Nat Rev Drug Discov. 2014 Feb;13(2):140-56. doi: 10.1038/nrd4204.
3
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.靶向PI3K/Akt/mTOR通路：有效联合方案及临床考量
Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50. doi: 10.1016/j.drup.2007.11.003. Epub 2007 Dec 31.
4
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.针对血液系统恶性肿瘤患儿的 PI3K/AKT/mTOR 信号通路。
Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000.
5
Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.针对恶性肿瘤中的 PI3K/Akt/mTOR 通路：原理与临床展望。
BioDrugs. 2014 Aug;28(4):373-81. doi: 10.1007/s40259-014-0090-5.
6
Development of PI3K inhibitors: lessons learned from early clinical trials.PI3K 抑制剂的开发：早期临床试验中获得的经验教训。
Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Epub 2013 Feb 12.
7
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.实体瘤中PI3K/AKT/mTOR信号通路的抑制作用
J Clin Oncol. 2016 Nov 1;34(31):3803-3815. doi: 10.1200/JCO.2014.59.0018. Epub 2016 Sep 30.
8
Targeting the PI3-kinase/Akt/mTOR signaling pathway.靶向PI3激酶/Akt/mTOR信号通路。
Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6.
9
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.针对乳腺癌中的磷脂酰肌醇 3-激酶信号通路。
Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15.
10
PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.PI3K/Akt/mTOR 通路抑制剂在癌症中的应用：临床进展展望。
Curr Med Chem. 2010;17(35):4326-41. doi: 10.2174/092986710793361234.
引用本文的文献
1
Mechanisms of fibrosis formation following glaucoma filtration surgery.青光眼滤过术后纤维化形成的机制。
Int J Ophthalmol. 2025 Aug 18;18(8):1579-1586. doi: 10.18240/ijo.2025.08.21. eCollection 2025.
2
Surface-tailored graphene nanosheets targeting PI3K/Akt signaling of breast cancer cells.靶向乳腺癌细胞PI3K/Akt信号通路的表面定制石墨烯纳米片
Sci Rep. 2025 Aug 13;15(1):29737. doi: 10.1038/s41598-025-00983-7.
3
Therapeutic Implications of Traditional Chinese Medicine in Clinically Relevant Diseases: Perspectives From microRNA-Modulated Apoptotic Signaling.中医在临床相关疾病中的治疗意义：基于微小RNA调控的凋亡信号转导视角
Drug Des Devel Ther. 2025 Aug 6;19:6719-6749. doi: 10.2147/DDDT.S511521. eCollection 2025.
4
The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia.肌醇-5-磷酸酶SHIP1：在急性淋巴细胞白血病中的表达、调控及作用
Int J Mol Sci. 2025 Jul 19;26(14):6935. doi: 10.3390/ijms26146935.
5
Piperine Induces Apoptosis and Cell Cycle Arrest via Multiple Oxidative Stress Mechanisms and Regulation of PI3K/Akt and MAPK Signaling in Colorectal Cancer Cells.胡椒碱通过多种氧化应激机制以及对PI3K/Akt和MAPK信号通路的调控诱导结肠癌细胞凋亡和细胞周期停滞。
Antioxidants (Basel). 2025 Jul 21;14(7):892. doi: 10.3390/antiox14070892.
6
Pilaralisib inhibits the replication of enteroviruses by targeting the PI3K/AKT signaling pathway.哌拉西利通过靶向PI3K/AKT信号通路抑制肠道病毒的复制。
Virol J. 2025 Jul 28;22(1):257. doi: 10.1186/s12985-025-02881-w.
7
Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted Therapies.乳腺癌的最新见解：分子途径、表观遗传调控及新兴靶向治疗
Breast Cancer (Auckl). 2025 Jul 13;19:11782234251355663. doi: 10.1177/11782234251355663. eCollection 2025.
8
Phenotypic and Functional Characterization of Oncohistone Mutations in Breast Cancers.乳腺癌中癌组蛋白突变的表型与功能特征
bioRxiv. 2025 May 3:2025.04.29.651098. doi: 10.1101/2025.04.29.651098.
9
Molecular Imprints of Clinical Comorbidities in Hypothalamic Extracellular Vesicles at the Onset of Obesity.肥胖症发病时下丘脑细胞外囊泡中临床合并症的分子印记
ACS Omega. 2025 May 29;10(22):23563-23581. doi: 10.1021/acsomega.5c02274. eCollection 2025 Jun 10.
10
Antioxidant and Anticancer Activities of L. f. From Siriya Kalvarayan Hills.来自西里亚卡尔瓦拉扬山的L. f. 的抗氧化和抗癌活性。
Scientifica (Cairo). 2025 May 28;2025:8055358. doi: 10.1155/sci5/8055358. eCollection 2025.
本文引用的文献
1
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.mTOR的活性位点抑制剂靶向mTORC1和mTORC2的雷帕霉素抗性输出。
PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.
2
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.mTOR复合物2是小鼠中由Pten缺失诱导的前列腺癌发生所必需的。
Cancer Cell. 2009 Feb 3;15(2):148-59. doi: 10.1016/j.ccr.2008.12.017.
3
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.一种ATP竞争性的雷帕霉素哺乳动物靶点抑制剂揭示了mTORC1的雷帕霉素抗性功能。
J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.
4
Targeting cancer with small molecule kinase inhibitors.用小分子激酶抑制剂靶向治疗癌症。
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
5
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.有效使用PI3K和MEK抑制剂治疗携带Kras G12D突变和PIK3CA H1047R突变的小鼠肺癌。
Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.
6
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.磷脂酰肌醇3激酶的过度激活导致拉帕替尼耐药，而mTOR/磷脂酰肌醇3激酶抑制剂NVP-BEZ235可逆转这种耐药性。
Cancer Res. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740.
7
Somatic mutations affect key pathways in lung adenocarcinoma.体细胞突变影响肺腺癌的关键通路。
Nature. 2008 Oct 23;455(7216):1069-75. doi: 10.1038/nature07423.
8
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.靶向多药理学：酪氨酸激酶和磷酸肌醇激酶双重抑制剂的发现
Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.
9
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.PIK3CA与其他磷脂酰肌醇3'-激酶途径突变协同作用以实现致癌转化。
Cancer Res. 2008 Oct 1;68(19):8127-36. doi: 10.1158/0008-5472.CAN-08-0755.
10
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.NVP-BEZ235，一种双PI3K/mTOR抑制剂，可阻止PI3K信号传导并抑制具有激活PI3K突变的癌细胞的生长。
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
Zotero 插件